Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

News

Home/News
7 12, 2015

BREAKING NEWS: Early data featuring Darzalex in combination with Revlimid

Tags: , , , |6 Comments

As promised, here are details from a preliminary study showing impressive response rates when Darzalex (daratumumab) is combined with Revlimid and dexamethasone. Similarly impressive numbers were also achieved when the immunotherapy drug was used along with pomalidomide. I'll pass along those details later today after that data is presented. Back to Darzalex and Revlimid. Very

4 12, 2015

Has bad timing left ASH irrelevant?

Tags: , , |2 Comments

I'm almost packed. Tomorrow I'll be driving three hours south to Orlando to attend my 7th American Society of Hematology (ASH) annual meeting. Seven years! How the multiple myeloma therapy landscape has changed. Heck, things have been turned upside down in three short weeks. The Washington Post ran an impressive article about it on Wednesday:

1 12, 2015

More about elotuzumab (Empliciti). Are immunotherapies the answer?

Tags: , , , , , |0 Comments

In my haste to get the news out about elotuzumab's FDA approval yesterday, I mistakenly relied on a Cure Magazine article that stated Kyprolis was the drug used in combination with elo. I was surprised, but ran with it. I should have known better. The Cure Magazine article was mistaken. Elotuzumab (Empliciti), Revlimid and dexamethasone

25 11, 2015

Financial aid: Takeda wants to help. Lets work together

Tags: , , , , , , , |6 Comments

I had an opportunity to interview several Takeda Pharmaceutical team members about the company's new oral, proteasome inhibitor, Ninlaro (ixazomib), yesterday afternoon. I have heard from dozens of patients who find themselves stuck paying thousands of dollars out-of-pocket for two established oral chemotherapy drugs, Revlimid and Pomalyst. I'm concerned that the same obstacles might face

16 11, 2015

BREAKING NEWS: FDA approves daratumumab

Tags: , , |0 Comments

I expected daratumumab to garner FDA approval sometime after ASH. So when I saw a news alert earlier today announcing that Darzalex had been approved, I didn't pay any attention. But it didn't take long for me to figure out that Darzalex is the new trade name for daratumumab. By any name, this is wonderful

16 11, 2015

Patient Snapshot Update: Transplant survivor David from Tampa

Tags: , |2 Comments

We've been following the progress of allogeneic (donor) stem cell transplant survivor, David, from Tampa, for a year. The young myeloma patient handled the difficult procedure better than most, but he openly expressed disappointment that his transplant didn't completely snuff out his cancer. I wrote about his thoughts in September: Patient Snapshot Update: David from

16 10, 2015

Great news!

Tags: , , |18 Comments

I met with Dr. Tricot this morning for my pre-transplant check. As expected, I'm good to go. I wasn't expecting such encouraging, eye-opening test results. The report from yesterday's PET scan still aren't available online. But Dr. Tricot had them. After he carefully examined me and double checked my numbers, Dr. Tricot flashed a big

14 10, 2015

Reader celebrating great response to daratumumab

Tags: , |10 Comments

I'm often said our readers are my best resource. Early reports about the new immunotherapy, daratumumab, have been good. Mike, from North Carolina, recently enrolled in a dara trial. He emailed me about how great it's working for him and agreed to share an email he sent his friends, trumpeting the early results. Here's a

12 10, 2015

We can’t wait for a cure!

Tags: |5 Comments

I had a chance to see myeloma patient and CrowdCare Foundation co-founder, Jenny Ahlstrom, in Boston last week. She made an impassioned plea to anyone that would listen to help her raise money to pay for two cutting edge T cell clinical trials; one in the U.S. and one in Germany. Here's information about the

7 10, 2015

Immunotherapy angst: Why is myeloma code so tough to crack?

Tags: , , |2 Comments

We were all so excited! Dying myeloma patient, Stacy from Minnesota, responded miraculously to Mayo Clinic's experimental measles vaccine therapy. Yet apparently attempts to match this early success is fleeting. U.S. News and World Report ran an excellent update yesterday about how researchers are mobilizing patient's immune systems to fight their cancer. The ongoing Mayo